Mylan Recalls Amlodipine and Benazepril Capsules Due to Manufacturing Deviations
Mylan Pharmaceuticals is recalling specific lots of Amlodipine Besylate and Benazepril HCl capsules because they were not manufactured according to Good Manufacturing Practices.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. According to the rubric, FDA Class II recalls involving significant injury/property-damage reports or structural defects are rated Severe (4). While specific injury reports are not detailed in the snippet, the CGMP deviation regarding active ingredients in a prescription drug carries a significant risk of harm, aligning with the Severe criteria for Class II drug recalls.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling 23,356 bottles of Amlodipine Besylate and Benazepril HCl Capsules, 10 mg/40 mg, 100-count bottles. The affected products are prescription-only and were distributed nationwide and in Puerto Rico. The recall involves specific lot numbers: 2003188, 2003189, 2003190, 2003191, and 3043498.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The source text states that the pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices. This classification indicates a potential risk that the medication may not be safe, effective, or of the quality it is supposed to be.
Consumers and healthcare providers should check their inventory for the specific NDC 0378-6900-01 and the listed lot numbers. If the product matches the recalled description, it should be returned to the pharmacy or supplier for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if they are currently using this medication.
The recalled product
- Product
- Amlodipine Besylate and Benazepril HCl Capsules, 10 mg/40 mg, 100-count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., NDC 0378-6900-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 23,356
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: 2003188
- 2003189
- 2003190
- 2003191
- 3043498
Distribution
Part of a larger recall action
This product is one of 12 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19